Drug patent disputes impede US access to cheaper biosimilars
An AAM report says costly US patent litigation is expected to leave 90 percent of the 118 biologics losing patent protection over the next decade without biosimilar competition. It could cost...To view the full article, register now.
Already a subscriber? Click here to view full article